Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel could keep your nose clear longer

NCT ID NCT07582328

Symptom relief Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gel form of the common decongestant oxymetazoline (found in many nasal sprays) in 120 healthy adults with a stuffy nose from colds or allergies. The gel is designed to stay in the nose longer than a spray. Researchers measured how well a single dose relieved congestion over two hours and checked for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxymetazoline hydrochloride 0.05% nasal gel
What this could lead to
If it works, this gel could offer longer-lasting relief from a stuffy nose compared to standard sprays.
What could go wrong
This is a small, early-phase trial. The gel may not work better than placebo, and side effects like nasal irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

120 people

The number who actually took part.

Started

Apr 2026

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants, age between 18 to 65 years at the time of signing the informed consent. * Participants in good general health per medical evaluation (medical, allergy, and social history; physical and nasal examinations). * Participants who self-report acute nasal congestion as symptoms of an acute upper respiratory tract infection or allergies and a VAS score meeting the study-defined threshold. * Participants should abstain from use of nicotine products or any forms of nicotine replacement therapy, and consuming alcohol at least 12 hours prior to the study. Exclusion Criteria: * Any of the following conditions: severe or unstable or uncontrolled cardiovascular disease, cerebral or coronary insufficiency, Raynaud's Syndrome, thromboangitis obliterans, scleroderma, Sjögren's syndrome, renal or hepatic impairment, thyroid disease, diabetes, chronic congestion, COVID, influenza and enlarged prostate. * Participants with narrow angle glaucoma. * History of nasal surgery or nasal abnormalities. * Participants with history of frequent nosebleeds or with rhinitis medicamentosa. * Females who are pregnant, breast feeding, or planning a pregnancy. * Participants with inflammation of the skin and mucosa of nasal vestibule and encrustation (rhinitis sicca). * Presence of acute or chronic illnesses that may affect sensory function. * A history of drug or alcohol abuse within 12 months prior to the study visit. * A positive drug /alcohol/CO test. * History of sensitivity/ anaphylaxis to any of the study medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasal congestion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Nasal Obstruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasal congestion Nasal congestion, nasal obstruction Nasal obstruction

Contacts and locations

Locations

  • Cliantha Research

    Mississauga, Ontario, L4W, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.